Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme and effects on the tolerability to Beta-blocker therapy in heart failure with reduced ejection fraction patients: Beta GenTURK Study

Zoghi, Mehdi; Kaya, Hakan; Çavuşoğlu, Yüksel; Aksakal, Enbiya; Demir, Şerafettin; Yücel, Celal; Mutlu, Haşim; Ergene, Oktay; Yılmaz, Mehmet; Study, Beta GenTURK

doi:10.5543/tkda.2016.10733

Cited by 1 publication

(1 citation statement)

References 39 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are registries in different cardiovascular diseases including one recent registry evaluating the overall HF patient profile, representative of Turkey (3). With regard to the management of HF, observational and retrospective data from tertiary care centers in Turkey designated that overall prescription rates for beta blockers (BBs) and renin-angiotensin-aldosterone system (RAAS) blockers were acceptable; however, target dose was rarely achieved among patients with HF (4). In Turkey, the "National Heart Health Policy" has been available since 2007; however, complete implementation is yet to be achieved.…”

Section: Introductionmentioning

confidence: 99%

Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality

et al. 2019

View full text Add to dashboard Cite

Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality Objective: Heart failure (HF) is a progressive clinical syndrome. SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey. Herein, all-cause mortality (ACM) data during follow-up were provided. Methods: This is a prospective outcome analysis of SELFIE-TR. Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF with reduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM. Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7-17) months. Survival data within 1 year were available in 1022 patients. Crude ACM was 19.9% for 1 year in the whole group. ACM within 1 year was 13.7% versus 32.6% in patients with CHF and AHF, respectively (p<0.001). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, and mineralocorticoid receptor antagonist were present in 70.6%, 88.2%, and 50.7%, respectively. In the whole cohort, survival curves were graded according to guideline-directed medical therapy (GDMT) scores ≤1 versus 2 versus 3 as 28% versus 20.2% versus 12.2%, respectively (p<0.001). Multivariate analysis of the whole cohort yielded age (p=0.009) and AHF (p=0.028) as independent predictors of mortality in 1 year. Conclusion: One-year mortality is high in Turkish patients with HF compared with contemporary cohorts with AHF and CHF. Of note, GDMT score is influential on 1-year mortality being the most striking one on chronic HFrEF. On the other hand, in the whole cohort, age and AHF were the only independent predictors of death in 1 year.

show abstract

Section: Introductionmentioning

confidence: 99%

Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality

et al. 2019

View full text Add to dashboard Cite

show abstract

Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme and effects on the tolerability to Beta-blocker therapy in heart failure with reduced ejection fraction patients: Beta GenTURK Study

Abstract: The frequency of Arg389Gly polymorphism in patients with HFREF in the present Turkish population differed from that of the healthy controls. However, neither Arg389Gly polymorphism nor Cyp2D6*10 polymorphism was associated with dose tolerability of BB therapy.

Cited by 1 publication

References 39 publications

Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality

Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality

Contact Info

Product

Resources

About